DARA BioSciences, Inc. to Present Results of a Clinical Study for KRN5500 at the “Annual Targeting Pain with Novel Therapeutics” Meeting Sponsored by Cambridge Healthtech Institute

RALEIGH, N.C., Feb. 22, 2010 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the results of its Phase 2 study has been identified by Cambridge Healthtech Institute ("CHI") for inclusion in its Annual "Targeting Pain with Novel Therapeutics" Conference.